Hodgkin lymphoma-a survey of children and adolescents treated in Sweden 1985-2009

Acta Oncologica

Volumn 54, Issue 1, 2015, Pages 41-48

  Englund, Annika ^a   Hopstadius, Charlotte ^a   Enblad, Gunilla ^a   Gustafsson, Göran ^b   Ljungman, Gustaf ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; MECHLORETAMINE; PREDNISONE; PROCARBAZINE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; CHLORMETHINE;

ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLASSICAL HODGKIN LYMPHOMA; DEATH; FEMALE; GROUPS BY AGE; HEALTH SURVEY; HODGKIN DISEASE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OVERALL SURVIVAL; RECURRENCE RISK; SEX DIFFERENCE; SEX RATIO; SURVIVAL RATE; SWEDEN; EPIDEMIOLOGY; INCIDENCE; MORTALITY; PATHOLOGY; PRESCHOOL CHILD; RECURRENT DISEASE; SURVIVAL ANALYSIS;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHILD; CHILD, PRESCHOOL; DACARBAZINE; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MECHLORETHAMINE; PREDNISONE; PROCARBAZINE; RECURRENCE; SEX DISTRIBUTION; SURVIVAL ANALYSIS; SWEDEN; VINBLASTINE; VINCRISTINE;

EID: 84919622542     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.948058     Document Type: Article

References (24)

1. Swedish Childhood Cancer Registry. G ustafsson G, Kogner P, Heyman M. Childhood cancer incidence and survival in Sweden 1984-2010. Report 2013. Stockholm: Karolinska Institutet; 2013
2. http://www.socialstyrelsen.se/statistik/statistikdatabas/cancer [Internet]. 2013 Dec
3. van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, et al. Long-term risk of second malignancy in survivors of hodgkins disease treated during adolescence or young adulthood. J Clin Oncol 2000;18:487-97
4. Swerdlow AJ, Barber J. A, Hudson G. V, Cunningham D, Gupta RK, Hancock BW, et al. Risk of second malignancy after hodgkins disease in a collaborative British cohort: The relation to age at treatment. J Clin Oncol 2000;18:498-509
5. Schellong G, Riepenhausen M, Bruch C, Kotthoff S, Vogt J, Bolling T, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 2010;55:1145-52
6. Galper S. L, Yu J. B, Mauch P. M, Strasser J. F, Silver B, Lacasce A, et al. Clinically signifi cant cardiac disease in patients with hodgkin lymphoma treated with mediastinal irradiation. Blood 2011;117:412-8
7. van Leeuwen-Segarceanu E. M, Dorresteijn L. D, Pillen S, Biesma DH, Vogels OJ, van Alfen N. Progressive muscle atrophy and weakness after treatment by mantle fi eld radiotherapy in hodgkin lymphoma survivors. Int J Radiat Oncol Biol Phys 2012;82:612-8
8. Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, et al. Gonadal function and fertility in survivors after hodgkin lymphoma treatment within the German hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 2013;31:231-9
9. van Beek RD, van Den Heuvel-Eibrink MM, Hakvoort-Cammel FG, van Den Bos C, van Der Pal HJ, Krenning EP, et al. Bone mineral density, growth, and thyroid function in long-term survivors of pediatric Hodgkins lymphoma treated with chemotherapy only. J Clin Endocrinol Metab 2009;94:1904-9
10. Mauz-Korholz C, Hasenclever D, Dorffel W, Ruschke K, Pelz T, Voigt A, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkins lymphoma: The GPOH-HD-2002 study. J Clin Oncol 2010;28:3680-6
11. Dorffel W, Ruhl U, Luders H, Claviez A, Albrecht M, Bokkerink J, et al. Treatment of children and adolescents with hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: Final results of the multinational trial GPOH-HD95. J Clin Oncol 2013;31:1562-8
12. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietiCand lymphoid tissues. Lyon, France: IARC Press; 2008
13. Diehl V, Sextro M, Franklin J, Hansmann ML, Harris N, Jaffe E, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkins disease and lymphocyte-rich classical Hodgkins disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkins Disease. J Clin Oncol 1999;17:776-83
14. Schwartz C. L. Special issues in pediatric Hodgkin s disease. Eur J Haematol Suppl 2005:55-62
15. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with hodgkins disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6
16. Kelly K. M, Hodgson D, Appel B, Chen L, Cole P. D, Horton T, et al. Childrens Oncology Groups 2013 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer 2013;60:972-8
17. Glimelius I, Molin D, Amini RM, Gustavsson A, Glimelius B, Enblad G. Bulky disease is the most important prognostic factor in hodgkin lymphoma stage IIB. Eur J Haematol 2003;71:327-33
18. Amini R. M, Enblad G, Gustavsson A, Ekman T, Erlanson M, Haapaniemi E, et al. Treatment outcome in patients younger than 60 years with advanced stages (IIB-IV) of hodgkins disease: The Swedish National Health Care Programme experience. Eur J Haematol 2000;65:379-89
19. Punnett A, Tsang RW, Hodgson DC. Hodgkin lymphoma across the age spectrum: Epidemiology, therapy, and late effects. Semin Radiat Oncol 2010;20:30-44
20. Sjoberg J, Halthur C, Kristinsson S. Y, Landgren O, Nygell UA, Dickman PW, et al. Progress in hodgkin lymphoma: A population-based study on patients diagnosed in Sweden from 1973-2009. Blood 2012; 119:990-6
21. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkins disease. International Prognostic Factors Project on Advanced Hodgkins Disease. N Engl J Med 1998;339:1506-14
22. Bazzeh F, Rihani R, Howard S, Sultan I. C omparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988-2005:An analysis of 21 734 cases. Leuk Lymph 2010; 51:2198-207
23. Jarrett R. F, Krajewski AS, Angus B, Freeland J, Taylor P. R, Taylor GM, et al. The Scotland and Newcastle epidemiological study of hodgkins disease: Impact of histopathological review and EBV status on incidence estimates. J Clin Pathol 2003;56:811-6
24. Glaser SL, Dorfman RF, Clarke CA. E xpert review of the diagnosis and histologic classification of hodgkin disease in a population-based cancer registry: Interobserver reliability and impact on incidence and survival rates. Cancer 2001;92:218-24